Scientific Forum
 

Download the SCIENTIFIC FORUM /in PDF/
 

Monday, June 22
08.30 - 09.00 Introduction
Koning F, Špičák J, Zima T, AOECS representatives
   
09.00 - 09.30 Keynote lecture
  Antigen-specific T cell receptors and disease susceptibility
Price D (UK)
   
09.30 - 10.30 Epidemiology
Chair:
Ivarsson A, Makharia GK
20 min What we have learned from  the epidemiological studies
Ivarsson A (Sweden)
20 min Celiac disease  in Asia
Makharia GK (India)
10 min Genome, Environment, Microbiome, and Metabolome biomarkers leading to the development of CD
Huedo-Medina T (USA)
10 min Different habits on gluten consumption in young European children
Crespo-Escobar P (Spain)
   
10.30 - 11.00 Coffee break
   
11.00 - 12.30 Diagnosis
Chair: Troncone R, Špičák J
20 min Evolving imaging tools and diagnosis of celiac disease
Špičák J (Czech Republic)
20 min Biomarkers for celiac disease
Troncone R (Italy)
10 min Prospective study on usefulness of duodenal bulb biopsies in coeliac disease diagnosis
Taavela J (Finland)
10 min Search for gluten non-dependent prospective biomarkers for in vitro diagnostic use
Korponay-Szabo I (Hungary)
10 min Celiac disease is underdiagnosed in sero-negative, gluten reacting, DQ2/8+ patients with Marsh I.
Røseth A (Norway)
10 min Clinical features and natural history of potential celiac disease in adults
Volta U (Italy)
10 min Presence of gluten peptides in urine reveals diet transgressions: correlation with mucosal damage
Rodríguez Herrera A (Spain)
   
12.30 - 13.30 Lunch/Poster tour
   
13.30 - 15.00 Epithelial cells and Pathogenesis I
Chair: Tlaskalova – Hogenován H, Cerf Bensussan N
20 min Wnt signaling in adult intestinal stem cells
Kořínek V (Czech Republic)
20 min T cells in celiac disease
Koning F (The Netherlands)
20 min B cells and celiac disease
Sollid LM (Norway)
10 min Identification and characterization of gluten reactive T cells from the immune repertoire
Yohannes D A (Finland)
10 min COUR-NP-GLI induce immune tolerance to gliadin and reduce gluten-dependent enteropathy in a celiac mouse model
Freitag T (Finland)
10 min The specificity of the T cell response to gluten is stable in celiac disease irrespective of age
Hardy M (Australia)
   
15.00 - 15.30 Coffee break
   
15.30 - 16.30 Genes
Chair: Wijmenga C,  Sollid LM
20 min Shared genetics in celiac disease and other autoimmunity disorders
Wijmenga C (The Netherlands)
10 min Fine-mapping in the MHC accounts for 18% of additional genetic risk for celiac disease
Zhernakova A (The Netherlands)
10 min Characterizing TCR ɣδ T cells in tissues and disease
Mayassi T (USA)
10 min Search for high risk gene variants by linkage and targeted resequencing in extended CD pedigrees
Saavalainen P (Finland)
10 min Gene expression studies in pediatric and adult celiac disease
Pascual V (Spain)
   
16.30 - 17.30 Extraintestinal associations
Chair: Bai J, Nevoral J
20 min Extraintestinal manifestations – introduction
Bai J (Argentina)
20 min Gluten-free diet and extraintestinal manifestation
Guandalini S (USA)
10 min Anemia and iron deficiency in children with potential celiac disease
Repo M (Finland)
10 min Increased prevalence of gluten-related disorders and early dysplasia in Barrett' esophagus
Pinto-Sanchez M I (Canada)
 
Tuesday, June 23
08.00 - 10.00 Pathogenesis II
Chair: Schuppan D, Jabri B
20 min Towards optimal model of celiac disease pathogenesis
Jabri B (USA)
20 min Beyond gluten: Role of ATIs in NCWS
Schuppan D (Germany)
20 min IL-15 in the pathogenesis of  celiac disease
Cerf Bensussan N (France)
10 min Role of Reovirus as an environmental trigger in the initiation of Celiac Disease
Bouziat R (USA)
10 min Macrophages favor differentiation of regulatory gliadin-specific IL-10 secreting Tr1 cells via IL-27
Costes L (The Netherlands)
10 min Small intestinal bacteria are involved in gluten metabolism in vivo
Caminero Fernandez A (Canada)
10 min Impact of Interleukin 15 (IL-15) on the development of intestinal dysbiosis
Meisel M (USA)
10 min Mechanisms of Host-Viral Interactions Mediating Loss of Oral Tolerance a prerequisite for CD
Hinterleitner R (USA)
10 min Intestinal epithelia lose barrier-function but gain migratory/invasive properties with IL-22
Schumann M (Germany)
   
10.00 - 10.30 Coffee break
   
10.30 - 11.00 Keynote lecture
  Autoimmunity: back to basics
Benoist Ch (USA)
   
11.00 - 12.20 Non-celiac gluten sensitivity
Chair: Lundin K, Verdu E
15 min Achievements and pitfalls of clinical studies
Lundin K (Norway)
15 min Response to gluten and patophysiology of IBS
Verdu E (Canada)
15 min There is more to wheat than gluten and more to NCGS than IBS
Gibson P (Australia)
10 min Response rate of functional patients after a double blind gluten challenge
Elli L (Italy)
10 min Gluten-free diet in patients with irritable bowel syndrome: a double-blind randomized placebo-control study
Shahbazkhani B, Rostami-Nejad M (Iran)
10 min Experimental autoimmune encephalopathy enhanced by dietary alpha-amylase/trypsin inhibitors (ATIs)
Zevallos V (Germany)
   
12.20 - 13.00 Lunch, poster tour
   
13.30 - 15.00 Mucosal healing, complications
Chair: Mulder CH, Murray JA
20 min Mucosal healing and mortality
Mulder Ch (The Netherlands)
20 min Modulation of intestinal epithelial repair
Murray  JA (USA)
10 min Prevalence of Comorbidities in Patients with Cœliac Disease
Guandalini S (USA)
10 min Primary prevention of type-1 diabetes mellitus by coeliac mass screening in children
Korponay-Szabo I (Hungary)
10 min Celiac disease autoimmunity in patients undergoing renal biopsies
Nurmi R (Finland)
10 min Prevalence and Predictors of Disordered Eating in Coeliac Disease
Satherley R-M (UK)
10 min Prevalence of functional GI symptoms among patients with celiac disease: a prospective study
Silvester JA (Canada)
   
15.00 - 15.30 Coffee break
   
15.30 - 17.00 Refractory CD, malignancies
Chair: Cellier C, Lebwohl B
20 min T cell lymphoma: progress in diagnosis and treatment
Cellier C (France)
20 min Mechanisms and possible modulation of nonresponsive celiac disease
Lebwohl B (USA)
10 min IL-15 and notch drive the differentiation of sCD3- IEL which undergo malignant transformation in CD
Meresse B (France)
10 min TNF synergizes with IL2 and IL21 to induce proliferation of aberrant IEL from RCDII patients
van Bergen J (The Netherlands)
10 min Autologous mesenchymal stem cell (MSC) infusions in refractory celiac disease (RCD): a case report
Ciccocioppo R (Italy)
10 min Revisiting diagnostic features of refractory celiac disease of type I
Cellier C (France)
10 min Autologous Stem Cell Transplantation (ASCT) for refractory coeliac disease II: The Irish Experience
Byrnes V (Ireland)

 

Wednesday, June 24
08.30 - 10.00 Primary prevention and screening
Chair: Mearin ML, Sandstrom O
20 min Screening for celiac disease: Yes, but…
Mearin ML (The Netherlands)
20 min Early infant feeding and prevention
Sandstrom O (Sweden)
10 min Risk of celiac disease in the first degree relatives of patients with celiac disease:A meta-analysis
Makharia G (India)
10 min Active Screening of Celiac Disease in At-Risk Children is Justified
Kivelä L (Finland)
10 min Screening for celiac disease in danish adults
Kårhus LL (Denmark)
10 min Elderly subjects screened for celiac disease adapt to and benefit from a gluten free diet
Cartee A (USA)
10 min Primary Care Testing for Coeliac Serology is No Better Than Population Screening
Chandler K (UK)
   
10.00 - 10.30 Coffee break
   
10 30 - 11.00 Keynote lecture
  Innate lymphoid cells in inflammation and immunity
Eberl G (France)
   
11.00 - 12.30 Novel treatments
Chair: Maki M, Fasano A
20 min Potential targets  to speed-up mucosal repair
Maki M (Finland)
20 min Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications
Fasano A (USA)
10 min A GFD Is Insufficient To Control Symptoms And Duodenal Injury In Many Patients With Celiac Disease
Adelman D (USA)
10 min BL-7010, a Novel Potential Treatment of Celiac Disease - a Phase 1/2 Safety Study in Celiac Patients
Nisemblat Y (Israel)
10 min Rationale for AMG 714, an anti-IL-15 mAb, in the treatment of celiac and refractory celiac disease
Leon F (USA)
10 min Discovery of CALY-002, best-in-class therapeutic antibody neutralizing human Interleukin-15
Vicari A (Switzerland)
10 min Engineering of Kuma030: a Potent Gliadin Endoprotease
Pultz I (USA)